How does VIP (Vasoactive Intestinal Peptide) work?
Endogenous 28-amino-acid neuropeptide. Binds VPAC1 and VPAC2 receptors expressed on immune cells, modulating both Th1/Th2 balance and inflammation. Used clinically (off-label US, on-label some EU contexts) for chronic inflammatory conditions. In plain terms, VIP (Vasoactive Intestinal Peptide) is endogenous 28-amino-acid neuropeptide. Modulates immune function and inflammation. Used in CIRS (chronic inflammatory response syndrome) protocols and biotoxin exposure recovery, popularized by Dr. Ritchie Shoemaker. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Users with CIRS or mold-illness contexts under medical guidance
- Chronic inflammatory conditions
- Post-biotoxin-exposure recovery (well-defined Shoemaker protocol)
References
- Vasoactive intestinal peptide (VIP) and inflammation, review — Delgado M & Ganea D, Amino Acids, 2013
- Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells — Sun X et al., World Journal of Gastroenterology, 2020
- Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis — Eger M et al., Frontiers in Pharmacology, 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on VIP (Vasoactive Intestinal Peptide)
Last updated 2026-06-06.